Clinical Trial

Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment

Name: Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment — clinical trial record (NCT07632209)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Aurora003

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.

Trial Details

NCT Number	NCT07632209
Lead Sponsor	Yayi He
Conditions	SCLC, Extensive Stage
Enrollment	46 participants
Start Date	2026-06
Primary Completion	2028-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-08